Psilocybin Safety Review Found More Acute Side Effects Than Comparators

A 2024 systematic review and meta-analysis in JAMA Network Open found that supervised psilocybin treatment was associated with increased risks of several acute adverse effects compared with study controls. The review offers a useful counterweight to benefit-focused headlines, while also showing how much remains unknown about uncommon and longer-term harms.

What the review included

Researchers combined six randomized, double-blind trials involving 528 participants treated for depression or anxiety. Their search covered publications available through November 30, 2023. Comparison conditions varied and included placebo, lower-dose psilocybin, or other comparators, so the pooled results do not describe one identical protocol.

The review found statistically significant increases in headache, nausea, anxiety, dizziness, and elevated blood pressure. For example, the pooled relative risk was approximately two for headache and 8.9 for nausea. These are relative measures, not the percentage of all patients who will experience each problem.

Relative risk needs context

A large relative increase can start from a low background frequency. Conversely, a modest relative increase can matter when a symptom is already common or particularly serious for a patient. Absolute event counts, comparator choice, and confidence intervals are therefore important when interpreting pooled estimates.

Some estimates were imprecise. The dizziness result had a particularly wide confidence interval, reflecting uncertainty about the size of the increase. Combining studies can improve statistical power, but it cannot eliminate weaknesses in adverse-event collection or make dissimilar treatment arrangements identical.

Most reported effects resolved quickly

The authors described the acute adverse-effect profile as generally tolerable, with effects resolving within 48 hours. That conclusion applies to the events captured in these monitored trials. It should not be simplified to 'psilocybin is safe' or 'all adverse effects disappear within two days.'

Clinical studies often screen out people with elevated medical or psychiatric risks. Participants also receive observation and support that may not exist outside research. The review therefore cannot establish the safety of unsupervised use, uncertain products, or treatment in populations underrepresented in the included studies.

What the review cannot rule out

A total of 528 participants is useful for studying some common short-term effects but insufficient to characterize very rare harms reliably. Acute monitoring also cannot answer every question about persistent perceptual symptoms, later psychiatric problems, repeated exposure, or consequences for everyday functioning.

The appropriate takeaway is neither alarm nor reassurance without qualification. Safety reporting needs to be systematic, long enough to capture delayed problems, and clear about severity and management. The research does not alter prescription rules or make state service licensing equivalent to FDA approval. For patients, honest counseling should discuss likely discomforts, serious uncertainties, individual risk factors, and a concrete plan for urgent care and follow-up—not simply whether a session is expected to feel difficult.

Sources

• JAMA Network Open: Acute adverse effects systematic review and meta-analysis
• NIDA: Psychedelic and dissociative drug health effects
• FDA: Clinical investigation considerations